戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ntibiotic in phase 3 trials for treatment of gonorrhoea).
2 and detection of new forms of drug-resistant gonorrhoea.
3 s a promising candidate for the treatment of gonorrhoea.
4 s 1 g oral azithromycin for the treatment of gonorrhoea.
5 reatment option for uncomplicated urogenital gonorrhoea.
6 axone plus azithromycin for the treatment of gonorrhoea.
7 tential to increase available treatments for gonorrhoea.
8 ible for the sexually transmitted infection, gonorrhoea.
9 syphilis, anorectal chlamydia, and anorectal gonorrhoea.
10 reatment option for uncomplicated urogenital gonorrhoea.
11  for the effective management and control of gonorrhoea.
12 ctions needed to retain our ability to treat gonorrhoea.
13 in in patients with uncomplicated urogenital gonorrhoea.
14 combined with azithromycin) for treatment of gonorrhoea.
15 or the treatment of uncomplicated urogenital gonorrhoea.
16  provide additional cross-protection against gonorrhoea.
17 rnatives to ceftriaxone for the treatment of gonorrhoea.
18 eness of the high frequency of oropharyngeal gonorrhoea.
19 cal group B vaccines affect the incidence of gonorrhoea.
20 e a vaccine has shown any protection against gonorrhoea.
21 uncomplicated genital, pharyngeal, or rectal gonorrhoea.
22 losporins raises the prospect of untreatable gonorrhoea.
23 lus azithromycin as first-line treatment for gonorrhoea.
24 ausing bacterial meningitis, septicaemia and gonorrhoea.
25 agent of the sexually transmitted infection, gonorrhoea.
26 ible target for novel antimicrobials against gonorrhoea.
27 st herpes simplex virus type 2, syphilis, or gonorrhoea.
28 ve agent of the sexually transmitted disease gonorrhoea.
29 3 cases, accounted for 50% of local cases of gonorrhoea.
30 es and clinical specimens from patients with gonorrhoea.
31 treatment with ceftriaxone for patients with gonorrhoea.
32 nd controls for analyses: 1241 incidences of gonorrhoea, 12 487 incidences of chlamydia, and 1002 inc
33 20.7%], n = 80); for urethral discharge were gonorrhoea (77.1% [95% CI: 68.1% to 84.1%], n = 68) and
34 er 100 person-years, 9.9-11.1) and anorectal gonorrhoea (9.7 cases per 100 person-years, 9.2-10.3).
35 imate vaccine effectiveness of MeNZB against gonorrhoea after adjustment for ethnicity, deprivation,
36    Using an outbreak of antibiotic resistant gonorrhoea amongst men have sex with men as a case study
37 he important sexually transmitted infection, gonorrhoea, an inflammatory condition of the genitourina
38 ve (4%) of these 121 men were diagnosed with gonorrhoea and 15 (12%) were diagnosed with chlamydia.
39 ps (21 cases per 100 person-years for rectal gonorrhoea and 28 cases per 100 person-years for rectal
40                                              Gonorrhoea and antimicrobial resistance (AMR) in Neisser
41 d impact of doxycycline PEP on the burden of gonorrhoea and antimicrobial resistance dynamics in men
42  physicians in both groups, treated baseline gonorrhoea and chlamydia infections, and assessed 9-mont
43 d chlamydia infections, and assessed 9-month gonorrhoea and chlamydia reinfection as the primary outc
44 5 men in the standard-of-care group received gonorrhoea and chlamydia testing (cOR 18.65, 9.78-35.54;
45 ay-it-forward strategy to increase uptake of gonorrhoea and chlamydia testing among MSM.
46 -it-forward programme, men were offered free gonorrhoea and chlamydia testing and given the option of
47 the standard-of-care group, men were offered gonorrhoea and chlamydia testing at the standard patient
48 ry outcome for this study was uptake of dual gonorrhoea and chlamydia testing, which we compared usin
49 n who have sex with men (MSM) rarely receive gonorrhoea and chlamydia testing.
50 for herpes simplex virus, ongoing trials for gonorrhoea and chlamydia vaccines, and the impact of exi
51 lly transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a sugg
52 d for HIV, syphilis, and rectal and urethral gonorrhoea and chlamydia.
53 s as a pooled specimen, for the diagnosis of gonorrhoea and chlamydia.
54  diseases including meningitis, septicaemia, gonorrhoea and endocarditis, and extracts haem from haem
55                                              Gonorrhoea and gonococcal antimicrobial resistance (AMR)
56 or the treatment of uncomplicated urogenital gonorrhoea and had a similar safety profile.
57 d be sensitive to the stigma associated with gonorrhoea and history of stigma experienced by MSM.
58 PS biosynthetic enzymes, LgtB from Neisseria gonorrhoea and LgtE from Neisseria meningitidis, and Lps
59 ithin the genus Neisseria cause the diseases gonorrhoea and meningitis.
60 ntly required to address increasing rates of gonorrhoea and the emergence and global spread of antibi
61 nces of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection were significantly l
62 he gonococcus, Gc) is the causative agent of gonorrhoea, and has evolved several systems for varying
63 the treatment of urogenital and extragenital gonorrhoea, are essential to inform treatment guidelines
64 commend that TOC be performed for anogenital gonorrhoea at least 7 or 14 days after administering the
65 r older with uncomplicated untreated genital gonorrhoea at two sites in Australia and one site in the
66      We included 77 patients; 5 self-cleared gonorrhoea before treatment and 10 were lost to follow-u
67 prospective vaccine development not only for gonorrhoea but also for meningococcal vaccines.
68  not appropriate as first-line treatment for gonorrhoea but remains potentially useful for patients w
69 eductions in the prevalence and incidence of gonorrhoea, but accelerated the spread of tetracycline r
70 oeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria
71                                              Gonorrhoea can present as urethritis in men, cervicitis
72 eisseria gonorrhoeae, the causative agent of gonorrhoea, can acquire iron by direct interaction with
73 c could be used again to treat a minority of gonorrhoea cases without raising resistance levels.
74  supported by the absence of oscillations in gonorrhoea cases, where a protective immune response is
75                             An oropharyngeal gonorrhoea CHIM is acceptable to key stakeholders but mu
76                    Overall, an oropharyngeal gonorrhoea CHIM was acceptable to most participants.
77  participation in the proposed oropharyngeal gonorrhoea CHIM, defined as healthy men who have sex wit
78 tic tests and new treatments, especially for gonorrhoea, chlamydia, and syphilis; designing new multi
79  of new HIV infections, 7% of incident STIs (gonorrhoea, chlamydia, and trichomoniasis) and 31% of te
80                           Key priorities for gonorrhoea control include strengthening prevention, ear
81 argeted for interventions aimed at improving gonorrhoea control, including returning travellers, sex
82 n of the potential role of the oropharynx in gonorrhoea control.
83          The development of an oropharyngeal gonorrhoea controlled human infection model (CHIM) could
84 oss-protection of the 4CMenB vaccine against gonorrhoea could be explained by cross-reaction against
85 o MeNZB was associated with reduced rates of gonorrhoea diagnosis, the first time a vaccine has shown
86 a, is essential to elucidate the dynamics in gonorrhoea epidemiology and gonococcal populations as we
87 ents, to elucidate recent changes in AMR and gonorrhoea epidemiology in Europe.
88 data is imperative to elucidate the shifting gonorrhoea epidemiology, both nationally and internation
89 a, and explain changes in gonococcal AMR and gonorrhoea epidemiology.
90       The development of new antibiotics for gonorrhoea, especially those with novel targets and no p
91  shows great promise to reduce the burden of gonorrhoea, even if the vaccine was only partially effec
92 ); and, (ii) semi-structured interviews with gonorrhoea experts.
93 orted to be associated with reduced rates of gonorrhoea following a mass vaccination campaign in New
94 ould explain the previously-seen decrease in gonorrhoea following MeNZB vaccination.
95 s recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which time resistan
96 pecific pathogens Neisseria meningitidis, N. gonorrhoea, Haemophilus influenzae and Moraxella catarrh
97 -STI testing and results service (chlamydia, gonorrhoea, HIV, and syphilis) on STI testing uptake and
98 s, rectal chlamydia in 14.6% (5.4-23.8), and gonorrhoea in 13.5% (3.2-23.8).
99                    Guidance for treatment of gonorrhoea in England and Wales was changed in 2010 to p
100 fected people contribute to the morbidity of gonorrhoea in the community.
101 icle meningococcal B vaccine (MeNZB) against gonorrhoea in young adults aged 15-30 years in New Zeala
102 , and had suspected uncomplicated urogenital gonorrhoea (including mucopurulent discharge), a positiv
103 e impact of a range of interventions against gonorrhoea, including increased condom use, more frequen
104 ug resistance phenotypes in a murine vaginal gonorrhoea infection model underscoring Debio 1453 as a
105                                              Gonorrhoea infection rates and the risk of infection fro
106            More empirical data on pharyngeal gonorrhoea infections, and the role of transmission to a
107                                              Gonorrhoea is a common infectious disease, poorly contro
108                                              Gonorrhoea is a common sexually transmitted infection fo
109             Development of a vaccine against gonorrhoea is a global priority, driven by the rise in a
110            Development of new treatments for gonorrhoea is a global public health priority.
111                                              Gonorrhoea is a highly prevalent sexually transmitted in
112                                              Gonorrhoea is a major global public health problem that
113                                              Gonorrhoea is a prevalent sexually transmitted infection
114                                   Control of gonorrhoea is becoming increasingly difficult, due to wi
115                       Effective treatment of gonorrhoea is fundamental to public health control; howe
116           The sexually transmitted infection gonorrhoea is on the rise worldwide and an increased und
117                                              Gonorrhoea is one of the most common bacterial sexually
118                                              Gonorrhoea (<0.1% prevalence in women and men) and HIV (
119 ity might be major contributors to community gonorrhoea morbidity.
120          The aetiological bacterial agent of gonorrhoea, Neisseria gonorrhoeae, has become resistant
121 ests for Chlamydia trachomatis and Neisseria gonorrhoea (nucleic acid amplification tests).
122 -up had significantly lower odds of combined gonorrhoea or chlamydia reinfection than did control pat
123 ligible to receive MeNZB, and diagnosed with gonorrhoea or chlamydia, or both.
124                       Women with symptomless gonorrhoea or chlamydial infection having an IUD inserte
125 ues are needed to accurately assess how oral gonorrhoea or saliva exchange in infected people contrib
126 nce rates (IRs) of any STI (i.e., chlamydia, gonorrhoea, or infectious syphilis) and individual STIs
127  9.6% (95% CI 7.9-11.7) and 9.9% (8.1-12.0), gonorrhoea prevalence 5.0% (3.8-6.7) and 8.4% (6.8-10.5)
128  (the gonococcus Gc), the causative agent of gonorrhoea, promotes attachment of the gonococcus to the
129 fetxt would reduce the risk of chlamydia and gonorrhoea reinfection at one year by improving three ke
130 was the cumulative incidence of chlamydia or gonorrhoea reinfection at one year, assessed by nucleic
131 ar, the cumulative incidence of chlamydia or gonorrhoea reinfection was 22.2% (693/3123) in the safet
132 xt intervention did not reduce chlamydia and gonorrhoea reinfections at one year in people aged 16-24
133                         Antibiotic-resistant gonorrhoea represents a global public health threat, and
134  been recommended in the UK for treatment of gonorrhoea since 2005.
135 ly transmitted infections (STIs): chlamydia, gonorrhoea, syphilis, and trichomoniasis.
136 m period, and 340 million people acquire new gonorrhoea, syphilis, chlamydia, or trichomonas infectio
137 seroconverted were diagnosed with chlamydia, gonorrhoea, syphilis, or new hepatitis C infection.
138 y recently acquired STIs included chlamydia, gonorrhoea, T. vaginalis and syphilis with rapid plasma
139 f all 121 men who tested, this was the first gonorrhoea test for 97 (80%) men and the first chlamydia
140 cross geographical boundaries to investigate gonorrhoea transmission and to track antimicrobial resis
141 ministic compartmental model, characterising gonorrhoea transmission in a US MSM population comprisin
142             We used a compartmental model of gonorrhoea transmission in a US population of men who ha
143 ul tool for epidemiological investigation of gonorrhoea transmission than earlier methods.
144 veral global action plans on AMR, new global gonorrhoea treatment recommendations, surveillance, and
145 ategies for introducing a new antibiotic for gonorrhoea treatment.
146 threatens the effectiveness of the available gonorrhoea treatments.
147 x virus type 2 (HSV-2), syphilis, chlamydia, gonorrhoea, Trichomonas vaginalis (together defined as '
148 ence of at least one curable STI (chlamydia, gonorrhoea, trichomonas, or high-titre syphilis) was 51%
149 9, and measured the prevalence of chlamydia, gonorrhoea, trichomonas, syphilis, and herpes simplex vi
150         We included patients with anogenital gonorrhoea visiting the Sexually Transmitted Infection C
151 ilis was 16.25% (95% CI 13.28-19.69), rectal gonorrhoea was 11.66% (9.14-14.66), and chlamydia was 20
152                                              Gonorrhoea was associated with the greatest concentratio
153 inical suspicion of uncomplicated urogenital gonorrhoea were eligible for inclusion.
154 e of ceftriaxone 500 mg for the treatment of gonorrhoea, when both drugs were combined with a 1 g dos
155 ses the sexually transmitted infection (STI) gonorrhoea, which has an estimated global annual inciden

 
Page Top